BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chastain CA, Beekmann SE, Wallender EK, Hulgan T, Stapleton JT, Polgreen PM. Hepatitis C Management and the Infectious Diseases Physician: A Survey of Current and Anticipated Practice Patterns. Clin Infect Dis 2015;61:792-4. [PMID: 25979310 DOI: 10.1093/cid/civ384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen YC, Thio CL, Cox AL, Ruhs S, Kamangar F, Wiberg KJ. Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study. BMJ Open 2019;9:e027411. [PMID: 30928964 DOI: 10.1136/bmjopen-2018-027411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Rapoport AB, Fischer LS, Santibanez S, Beekmann SE, Polgreen PM, Rowley CF. Infectious Diseases Physicians' Perspectives Regarding Injection Drug Use and Related Infections, United States, 2017. Open Forum Infect Dis 2018;5:ofy132. [PMID: 30018999 DOI: 10.1093/ofid/ofy132] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
3 Chan J, Young J, Cox J, Nitulescu R, Klein MB. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. CanLivJ 2018;1:231-9. [DOI: 10.3138/canlivj.2018-0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Allyn PR, O'Malley SM, Ferguson J, Tseng CH, Chew KW, Bhattacharya D. Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Int J STD AIDS 2018;29:334-40. [PMID: 28820346 DOI: 10.1177/0956462417725462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Simoncini GM, Hou Q, Carlson K, Buchacz K, Tedaldi E, Palella F , Jr, Durham M, Li J; HIV Outpatient Study (HOPS) Investigators. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018. AIDS Patient Care STDS 2021;35:392-400. [PMID: 34623891 DOI: 10.1089/apc.2021.0087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 McLaughlin MM, Marx KT, Terriff C; American Academy of HIV Medicine Pharmacists Committee. Improving patient access to hepatitis C virus treatment. J Am Pharm Assoc (2003) 2018;58:109-112.e1. [PMID: 29154018 DOI: 10.1016/j.japh.2017.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH. Hepatitis C Management and the Infectious Diseases Pharmacist. Clin Infect Dis 2015;61:1201-2. [PMID: 26136390 DOI: 10.1093/cid/civ545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Adams LM, Balderson B, Packett BJ 2nd. Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers. AIDS Patient Care STDS 2018;32:314-20. [PMID: 30067406 DOI: 10.1089/apc.2018.0006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 2019;31:1340-7. [PMID: 30829533 DOI: 10.1080/09540121.2019.1587353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]